or Try an Advanced Search...

    Refractory Acute Myeloid Leukemia Stocks List

    Symbol Grade Name % Change
    XBIO A Xenetic Biosciences, Inc. 7.25
    SYRS D Syros Pharmaceuticals, Inc. -7.63
    CRBU F Caribou Biosciences, Inc. 0.00
    MBRX F Moleculin Biotech, Inc. 5.69
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Acute Myeloid Leukemia Biopharmaceutical Biotechnology Cancer Leukemia Medicine Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Acute Leukemia Anemia Antineoplastic Drugs Blastoma Breakthrough Therapy CD19 Cancer Immunotherapy Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Chronic Kidney Disease Clinical Medicine

    Related ETFs - A few ETFs which own one or more of the above listed Refractory Acute Myeloid Leukemia stocks.

    Symbol Grade Name Weight
    CNCR D Loncar Cancer Immunotherapy ETF 1.01
    WDNA D WisdomTree BioRevolution Fund 0.98
    GNOM D Global X Genomics & Biotechnology ETF 0.61
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 0.54
    IDNA D iShares Genomics Immunology and Healthcare ETF 0.4
    View all Refractory Acute Myeloid Leukemia ETFs...
    Compare ETFs
    Compare BBC to IDNA Compare CNCR to BBC Compare CNCR to IDNA

        Refractory Acute Myeloid Leukemia Stocks Recent News

        Date Stock Title
        Apr 18 CRBU Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
        Apr 18 MBRX Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
        Apr 18 MBRX European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
        Apr 15 CRBU Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
        Apr 12 SYRS The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
        Related Industries: Biotechnology
        Related Stock Lists: Acute Myeloid Leukemia Biopharmaceutical Biotechnology Cancer Leukemia Medicine Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Acute Leukemia Anemia Antineoplastic Drugs Blastoma Breakthrough Therapy CD19 Cancer Immunotherapy Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Chronic Kidney Disease Clinical Medicine
        Refractory Acute Myeloid Leukemia

        Refractory Acute Myeloid Leukemia (AML) is a type of cancer of the blood and bone marrow that is resistant to standard treatments. It is a rare and aggressive form of leukemia that is difficult to treat and has a poor prognosis. Symptoms of AML include fatigue, fever, weight loss, and anemia. Treatment options for refractory AML include chemotherapy, stem cell transplant, and targeted therapies.

        Browse All Tags